Merck & Co. (MRK) : Albion Financial Group Ut scooped up 2,028 additional shares in Merck & Co. during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Apr 21, 2016. The investment management firm now holds a total of 58,911 shares of Merck & Co. which is valued at $3,342,610.Merck & Co. makes up approximately 0.55% of Albion Financial Group Ut’s portfolio.
Merck & Co. opened for trading at $56.06 and hit $56.62 on the upside on Wednesday, eventually ending the session at $56.31, with a gain of 0.48% or 0.27 points. The heightened volatility saw the trading volume jump to 69,41,426 shares. Company has a market cap of $156,275 M.
Other Hedge Funds, Including , Pm Capital Ltd reduced its stake in MRK by selling 7,500 shares or 2.46% in the most recent quarter. The Hedge Fund company now holds 297,000 shares of MRK which is valued at $16,851,780. Merck & Co. makes up approx 2.73% of Pm Capital Ltd’s portfolio.Trillium Asset Management boosted its stake in MRK in the latest quarter, The investment management firm added 126,675 additional shares and now holds a total of 309,917 shares of Merck & Co. which is valued at $17,584,691. Merck & Co. makes up approx 1.14% of Trillium Asset Management’s portfolio. First Western Capital Management Co sold out all of its stake in MRK during the most recent quarter. The investment firm sold 5,053 shares of MRK which is valued $286,707.Dividend Asset Capital reduced its stake in MRK by selling 1,830 shares or 29.93% in the most recent quarter. The Hedge Fund company now holds 4,285 shares of MRK which is valued at $243,131. Merck & Co. makes up approx 0.01% of Dividend Asset Capital’s portfolio.Van Cleef Asset Managementinc reduced its stake in MRK by selling 75 shares or 0.31% in the most recent quarter. The Hedge Fund company now holds 24,259 shares of MRK which is valued at $1,376,456. Merck & Co. makes up approx 0.48% of Van Cleef Asset Managementinc’s portfolio.
On the company’s financial health, Merck & Co. reported $0.93 EPS for the quarter, beating the analyst consensus estimate by $ 0.02 according to the earnings call on Feb 3, 2016. Analyst had a consensus of $0.91. The company had revenue of $10215.00 million for the quarter, compared to analysts expectations of $10355.20 million. The company’s revenue was down -2.5 % compared to the same quarter last year.During the same quarter in the previous year, the company posted $0.87 EPS.
Many Wall Street Analysts have commented on Merck & Co.. Societe Generale Initiated Merck & Co. on Apr 6, 2016 to “Buy”, Price Target of the shares are set at $80.Merck & Co. was Downgraded by BofA/Merrill to ” Neutral” on Jan 27, 2016.
Merck & Co. Inc. is a global health care company. The Company offers health solutions through its prescription medicines vaccines biologic therapies and animal health products which it markets directly and through its joint ventures. The Companys Pharmaceutical segment includes human health pharmaceutical and vaccine products marketed either directly by the Company or through joint ventures. Human health pharmaceutical products consist of therapeutic and preventive agents generally sold by prescription for the treatment of human disorders. The Company sells these human health pharmaceutical products primarily to drug wholesalers and retailers hospitals government agencies and managed health care providers. The Animal Health segment discovers develops manufactures and markets animal health products including vaccines. The Companys animal health products are sold to veterinarians distributors and animal producers.